Skip to content
OpenCapital
Get started

QuidelOrtho Corporation QDEL Payments for Restructuring

Payments for Restructuring at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$17.3M+20.8%
Revvity logo
RevvityRVTY
——
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$832.61M-56.1%
Enterprise value$3.8B-22.0%
P/S0.3×-0.4×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%—

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRestructuring.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's payments for restructuring.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's payments for restructuring?
QuidelOrtho Corporation (QDEL) reported payments for restructuring of $700K in Q1 2026.
What does payments for restructuring mean?
Measures the actual cash outflow associated with executing restructuring plans, such as severance payments or facility exit costs. This metric is critical for assessing the cash impact of organizational transformation initiatives.